Medy-Tox Inc. (KOSDAQ:086900)
South Korea · Delayed Price · Currency is KRW 77,300
-700 (-0.90%)
Aug 12, 2026, 3:30 PM KST
Medy-Tox Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 244,021 | 247,290 | 228,622 | 221,121 | 195,096 | 184,870 |
Revenue Growth | 2.53% | 8.17% | 3.39% | 13.34% | 5.53% | 31.27% |
Gross Profit Gross Profit Growth | 146,538 | 142,841 | 138,584 | 133,496 | 126,048 | 105,473 |
Operating Income Operating Income Growth | 18,574 | 16,679 | 20,349 | 17,322 | 46,665 | 33,138 |
Net Income Net Income Growth | 19,610 | 15,619 | 15,980 | 8,780 | 36,035 | 93,179 |
Earnings Per Share EPS Growth | 3271.97 | 2371.01 | 2376.57 | 1311.00 | 5489.34 | 14517.37 |
EPS Growth | 6.27% | -0.23% | 81.28% | -76.12% | -62.19% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
South Korea South Korea Growth | 88,465 | 90,717 | 84,208 | 79,821 | 66,704 | 59,716 |
Foreign Country Foreign Country Growth | 151,496 | 152,575 | 140,564 | - | - | - |
Total Total Growth | 239,960 | 243,292 | 224,771 | 217,160 | 191,465 | 182,073 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 42,533 | 48,945 | 59,515 | 33,345 | 26,208 | 81,927 |
Total Debt Total Debt Growth | 125,327 | 76,630 | 81,318 | 82,830 | 120,862 | 132,917 |
Net Cash (Debt) Net Cash Growth | -82,794 | -27,685 | -21,803 | -49,485 | -94,654 | -50,990 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -13814.15 | -4202.59 | -3242.53 | -7389.19 | -14418.99 | -7944.34 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 68,922 | 61,410 | 36,556 | 13,522 | 26,199 | 19,966 |
Capital Expenditures CapEx Growth | -14,683 | -15,661 | -8,726 | -7,660 | -9,895 | -17,514 |
Free Cash Flow Free Cash Flow Growth | 54,238 | 45,749 | 27,830 | 5,862 | 16,304 | 2,452 |
Free Cash Flow Growth | 77.88% | 64.39% | 374.76% | -64.05% | 564.95% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 60.05% | 57.76% | 60.62% | 60.37% | 64.61% | 57.05% |
Operating Margin | 7.61% | 6.74% | 8.90% | 7.83% | 23.92% | 17.93% |
Pretax Margin | 4.81% | 2.66% | 7.65% | 7.17% | 25.39% | 69.38% |
Profit Margin | 8.04% | 6.32% | 6.99% | 3.97% | 18.47% | 50.40% |
FCF Margin | 22.23% | 18.50% | 12.17% | 2.65% | 8.36% | 1.33% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 23.84 | 54.29 | 52.01 | 184.70 | 22.37 | 9.40 |
Forward PE | 17.91 | 35.44 | 19.78 | 31.76 | 27.88 | 23.25 |
P/FCF Ratio | 9.37 | 18.54 | 29.86 | 276.65 | 49.45 | 357.35 |
PS Ratio | 2.08 | 3.43 | 3.64 | 7.33 | 4.13 | 4.74 |